Equities research analysts at Cantor Fitzgerald boosted their price target on shares of Salix Pharmaceuticals (NASDAQ:SLXP) from $77.00 to $80.00 in a research note issued to investors on Monday, American Banking News.com reports. The firm currently has a “hold” rating on the stock. Cantor Fitzgerald’s price target suggests a potential downside of 6.14% from the stock’s previous close.
SLXP has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note to investors on Monday. They now have a $88.00 price target on the stock. Separately, analysts at Mizuho raised their price target on shares of Salix Pharmaceuticals from $85.00 to $101.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Brean Capital raised their price target on shares of Salix Pharmaceuticals from $76.00 to $90.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $78.86.
Salix Pharmaceuticals (NASDAQ:SLXP) traded up 1.46% on Monday, hitting $85.23. The stock had a trading volume of 2,160,807 shares. Salix Pharmaceuticals has a 1-year low of $39.12 and a 1-year high of $85.02. The stock’s 50-day moving average is $71.01 and its 200-day moving average is $66.42. The company has a market cap of $5.256 billion and a P/E ratio of 68.80.
Salix Pharmaceuticals (NASDAQ:SLXP) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.86 by $0.03. The company had revenue of $238.20 million for the quarter, compared to the consensus estimate of $239.70 million. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was up 28.7% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $3.24 earnings per share for the current fiscal year.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.